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Outcome of SARS-CoV-2 virus-infected organ transplant recipients - results of the BECOVSOT 
registry 
K. M. Wissing, D. Van Raemdonck, M. Naesens, C. Bonvoisin, N. Kanaan, N. Boon, R. Hellemans, P. 
Hendrikx, N. Grossen, D. Claes, M-H. Delbouille, Th. Timmermans, P. Hollants, J. Duarta, L. Weekers 
(Belgian Transplantation Society) 
 
At the start of the SARS-COV-2 virus epidemic in February 2020 the Belgian Transplantation society 
set up a retrospective follow up registry to collect data on the incidence of SARS-COV-2 infection in 
solid organ transplant recipients and on key outcomes of these patients in terms of hospitalization, 
intensive care, need for assisted ventilation and mortality. Between 13/02/2020 and 12/04/2021, 
416 cases of SARS-COV-2 infection were reported in six Belgian transplant centres (Kidney 56%, Liver 
15%, Lung 11%, Heart 10%, Combined 6%). The distribution of infections in transplant recipients 
mirrored the general population, with 2 waves peaking in April and November 2020. Mean age was 
57.4±14.7 years and did not differ among organs. Fifty-five % of patients (N=228) were hospitalized 
and 14% (N=59) required intensive care. Forty patients (68%) received either assisted ventilation 
and/or ECMO therapy. Median duration of hospitalization was 10 days for the overall cohort but 
increased to 18.5 days in case of need for intensive care. For the overall cohort the Kaplan Meier 
estimate of death at 90 days after diagnosis was 16.3% (95%CI 12.9 to 20.5%). Type of organ 
transplant was not associated with the risk of death. Older age and need for intensive care were the 
main predictors for increased mortality. Survival 90 days after diagnosis was 28.6% (95%CI 17.5-
40.6%) in patients requiring hospitalization in ICU. Infection with SARS-COV-2 virus is a serious 
condition in transplant recipients frequently resulting in prolonged hospitalization and high mortality. 
The impact of vaccination and new anti-viral therapies on the incidence of COVID-19 disease related 
outcomes should be monitored. 
 
 
Long-term outcome of liver transplantation for neuroendocrine tumour non-resectable liver 
metastases: a Belgian retrospective multi-centre study 
E. Bonaccorsi-Riani, I. Cloquell, O. Detry, N. Meurisse, D. Ysebaert, Ch. Verslype, J. Pirenne, F. 
Berrevoet, A. Vanlander, V. Lucidi, I. Borbat (UCL, ULg, UA, KUL, UG, ULB) 
 
Liver transplantation (LT) is the only curative treatment for non-resectable liver metastases from 
neuroendocrine tumours (NET-Liver-mets). The adoption of strict indication criteria improves long-
term survival. We retrospectively reviewed the medical records of all of patients who underwent LT 
by NET-mets at the six LT centres in Belgium from 1986 to 2020. Patient and tumour characteristics, 
indication for transplantation and surgical techniques, long-term survival of the patient, and tumour 
recurrence rate were analysed to identify prognostic factors to improve our guidelines. Forty patients 
underwent a LT for NET-Liver-mets in Belgium. Most patients were male (74.2%) with a mean age of 
41.9 and 47.1 years at the time of NET diagnosis and liver transplantation, respectively. The location 
of the primary tumour was mainly the pancreas in 57.5%, followed by the small intestine in 25% of 
the cases, and in 84% of the patients the primary tumour was resected before LT. The post-LT overall 
patient survival rate at 1, 5, and 10 years are: 84,3%, 65,0% and 54,6% respectively, while the overall 
disease-free survival are 76,3%, 44,5% and 38.2 in the same intervals. However, the survival rate of 
transplant patients after 2010 at 1, 5 and 10 years is 84.2%, 74.8 and 74.8% compared to 85%, 60.0% 
and 49, 5% of transplanted patients before 2010. These findings suggest an improvement in the long-
term survival rate for patients undergoing LT after 2010. In conclusion, our study shows that LT is a 
valid treatment for non-resectable liver metastasis from neuroendocrine tumours. 
 
 
Anastomosis time is a risk factor for primary graft dysfunction after double lung transplantation: a 
clinical retrospective cohort study. 
Ch. Vandervelde, R. Vos, St. Fieuws, St.Verleden, J. Van Slambrouck, P. De Leyn, W. Coosemans, Ph. 
Nafteux, H. Decaluwé, H. Van Veer, L. Depypere, D. Dauwe, E. De Troy, C. Ingels, A. Neyrinck, B. 
Vanaudenaerde, L. Godinas, G. Verleden, D. Van Raemdonck, L. Ceulemans (KUL, UA) 
 
Primary graft dysfunction (PGD), graded 0 to 3, is a major obstacle after lung transplantation (LTx) 
and is associated with increased early morbidity and mortality. Different studies in liver and kidney 
transplantation revealed prolonged anastomosis time (AT) as an independent risk factor for impaired 
short-term outcome. We investigated if AT during LTx is a risk factor for development of PGD. In this 
retrospective single centre cohort study we included all first sequential single-lung transplantations 
(SSLTx) between 2008 and 2016. The association of AT with any PGD grade 3 within the first 72 hours 
post-transplant was analysed by univariable and multivariable logistic regression analysis. Results: 
Data on AT and PGD was available for 451 patients. PGD 3 occurred in 138 patients. AT was 
independently associated with development of PGD 3 in univariable (odds ratio (OR) per minute 
1.025, 95%CI (1.012-1.037), p=0.0001) and multivariable (OR per minute 1.019, 95%CI (1.003-1.034), 
p=0.016) logistic regression analysis. There was no evidence that the relation between AT and PGD 
differed between recipients from donation after brain death versus donation after circulatory death 
donor lungs.  
This study identified for the first time AT as independent risk factor for development of PGD 3 post-
SSLTx. We suggest that the implantation time should be kept short and the lung cool to decrease 
PGD-related morbidity and mortality post-SSLTx. 
 
 
Peripheral blood transcriptomic profiles demonstrate peripheral blood leukocyte activation at time 
of antibody-mediated rejection and polyomavirus nephropathy after kidney transplantation 
E. Van Loon, W. Gwinner, D. Anglicheau, P. Marquet, M. Naesens (Hannover, Paris, Limoges, KUL) 
 
Kidney transplant injury processes are associated with molecular changes in renal tissue, primarily 
related to immune cell activation and infiltration. How these processes are reflected by molecular 
alterations in circulating immune cells is poorly understood. Methods: We performed RNA-
sequencing on 384 biobanked blood samples from four transplant centres, taken at time of a kidney 
allograft biopsy, selected for their phenotype (acute T cell- and antibody-mediated rejection, 
polyomavirus-associated nephropathy, and control). We performed differential expression analysis 
and pathway analysis per phenotype. The abundance of involved cell types was quantified by xCell. 
We integrated the blood results with microarray analysis of 224 kidney allograft biopsies. Results: In 
peripheral blood, 72 differentially expressed genes (FDR P-value <0.05) in rejection (N=136) vs. no 
rejection (N=248) samples demonstrated upregulation of glucocorticoid receptor and NOD-like 
receptor signalling pathways. Pathways enriched in antibody-mediated rejection were strongly 
immune-specific, whereas pathways enriched in T cell-mediated rejection were less immune related. 
Differentially expressed genes in polyoma viremia and polyomavirus-associated nephropathy were 
similar and demonstrated upregulation of mitochondrial dysfunction and interferon signalling 
pathways. The top differentially expressed genes for the rejection subtypes were consistent between 
